

108TH CONGRESS  
1ST SESSION

# H. R. 3155

To amend the Internal Revenue Code of 1986 to deny any deduction for direct-to-consumer advertisements of prescription drugs that fail to provide certain information or to present information in a balanced manner, and to amend the Federal Food, Drug, and Cosmetic Act to require reports regarding such advertisements.

---

## IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 23, 2003

Mr. STARK (for himself, Mr. EMANUEL, and Mr. GRIJALVA) introduced the following bill; which was referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To amend the Internal Revenue Code of 1986 to deny any deduction for direct-to-consumer advertisements of prescription drugs that fail to provide certain information or to present information in a balanced manner, and to amend the Federal Food, Drug, and Cosmetic Act to require reports regarding such advertisements.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2       This Act may be cited as the “Fair Balance Prescrip-  
3 tion Drug Advertisement Act of 2003”.

4 **SEC. 2. DISALLOWANCE OF DEDUCTION FOR DIRECT-TO-**  
5 **CONSUMER ADVERTISEMENT OF PRESCRIP-**  
6 **TION DRUG THAT FAILS TO PROVIDE CER-**  
7 **TAIN INFORMATION OR TO PRESENT BAL-**  
8 **ANCED INFORMATION.**

9       (a) **GENERAL RULE.**—Part IX of subchapter B of  
10 chapter 1 of the Internal Revenue Code of 1986 (relating  
11 to items not deductible) is amended by adding at the end  
12 thereof the following new section:

13 **“SEC. 280I. DIRECT-TO-CONSUMER ADVERTISEMENT OF**  
14 **PRESCRIPTION DRUG THAT FAILS TO PRO-**  
15 **VIDE CERTAIN INFORMATION OR TO**  
16 **PRESENT BALANCED INFORMATION.**

17       “No deduction shall be allowed under this chapter for  
18 any expense of an advertisement for a prescription drug  
19 if, with respect to such advertisement, the Secretary of  
20 Health and Human Services has submitted to the Sec-  
21 retary of the Treasury a report under section 311 of the  
22 Federal Food, Drug, and Cosmetic Act.”

23       (b) **CLERICAL AMENDMENT.**—The table of sections  
24 for part IX of subchapter B of chapter 1 of such Code  
25 is amended by adding at the end thereof the following new  
26 item:

“Sec. 280I. Direct-to-consumer advertisement of prescription drug that fails to provide certain information or to present balanced information.”

1 (c) EFFECTIVE DATE.—The amendments made by  
2 this section shall apply to amounts paid or incurred after  
3 December 31, 2003.

4 **SEC. 3. PROHIBITIONS REGARDING DIRECT-TO-CONSUMER**  
5 **PRESCRIPTION DRUG ADVERTISING; RE-**  
6 **PORTING OF VIOLATIONS TO INTERNAL REV-**  
7 **ENUE SERVICE.**

8 Chapter III of the Federal Food, Drug, and Cosmetic  
9 Act (21 U.S.C. 331 et seq.) is amended by adding at the  
10 end the following section:

11 “PROHIBITIONS REGARDING DIRECT-TO-CONSUMER PRE-  
12SCRIPTION DRUG ADVERTISING; REPORTING OF VIO-  
13LATIONS TO INTERNAL REVENUE SERVICE

14 “SEC. 311. With respect to a direct-to-consumer ad-  
15vertisement of a prescription drug, the Secretary shall re-  
16port to the Secretary of the Treasury—

17 “(1) any violation of section 301 involving the  
18misbranding of the prescription drug by reason of  
19failure to comply with the requirements of section  
20502(n) that relate to the provision in the advertise-  
21ment of true statements relating to side effects, con-  
22traindications, and effectiveness; or

23 “(2) any determination by the Secretary, made  
24upon a petition of an interested person or the Sec-

1       retary's own initiative, that under criteria estab-  
2       lished by the Secretary by regulation, the portion of  
3       the advertisement devoted to describing side effects,  
4       contraindications, or any lack of effectiveness is less  
5       than the portion of the advertisement devoted to de-  
6       scribing the benefits of the drug, taking into account  
7       the amount and type size of any printed informa-  
8       tion, whether all printed material is printed together  
9       or on facing or consecutive pages, the duration of  
10      the advertisement (in the case of an advertisement  
11      through media such as television or radio), and such  
12      other factors as the Secretary determines to be ap-  
13      propriate.”.

○